GANX had been in a tight consolidation channel prior to April 12th. This is the
uncommon high tight flag pattern. Once breaking out, the typical guidance is
the next leg up will be at least the distance of the flagpole portion of the pattern.
On April 12th, a new chief financial officer was appointed to Gain Therapeutics.
( see the link below )
This is...
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded...